“The Metabolic Resuscitation Protocol”.
A large body of experimental data has demonstrated that both corticosteroids and intravenous vitamin C reduce activation of nuclear factor kB (NF-kB) attenuating the release of pro-inflammatory mediators, reduce the endothelial injury characteristic of sepsis thereby reducing endothelial permeability and improving microcirculatory flow, augment the release of endogenous catecholamine’s and enhance vasopressor responsiveness.[1-8] In animal models these effects have resulted in reduced organ injury and increased survival. Corticosteroids have been evaluated in several clinical trials, with meta-analysis of these trials demonstrating somewhat conflicting outcomes. [9,10] Low-dose stress corticosteroids have proven to be safe with no increased risk of clinically important complications. While corticosteroids decrease vasopressor dependency the effect on the risk of developing organ failure and survival is less clear. Similarly intravenous Vitamin C has been evaluated in unselected surgical ICU patients,  patients with burns  those with pancreatitis  and in two pilot studies of patients with severe sepsis and septic shock. [14,15] In general these studies have demonstrated a reduction in the risk of multisystem organ failure (MSOF) although the effect on mortality is less clear. However, IV vitamin C was shown to be extremely safe with no recorded complications.
In vitro data has suggested that vitamin C and hydrocortisone may act synergistically (see also study below).[16-18] Barabutis et al have demonstrated that hydrocortisone together with vitamin C protects the vascular endothelium from damage by endotoxin while neither agent alone had this effect.  Based on these clinical and experimental data we initiated a treatment protocol for patients with severe sepsis and septic shock that included intravenous vitamin C, hydrocortisone and thiamine. We have demonstrated reproducibly and consistently that this therapeutic cocktail reverses the organ dysfunction of sepsis with a marked reduction in mortality. This protocol has now been adopted at multiple centers across the world with remarkably consist and reproducible results.
Ascorbate donates a single electron in all its redox reactions, generating the ascorbate radical. This radical is not very reactive with anything but itself. Dismutation of two ascorbate radicals forms a molecule each of ascorbate and dehydroascorbate. Hydrolysis of the lactone ring of dehydroascorbate irreversibly converts it to 2,3-diketo-1-gulonic acid which is then converted to oxalate. Oxalate is normally excreted by the kidney and serum levels will increase with renal impairment. In patients with renal impairment receiving mega-dose vitamin C ( > 50g), supersaturation of serum with oxalate may result in tissue deposition as well as crystallization in the kidney. [22,23] Glyoxylate, a byproduct of intermediary metabolism, is either reduced to oxalate or oxidized to CO2 by the enzyme glyoxylate aminotransferase; thiamine pyrophosphate is a co-enzyme required for this reaction.  Thiamine deficiency increases the conversion of glyoxylate to oxalate resulting in hyper-oxalosis. [25,26] In addition, thiamine is an essential co-enzyme for many of the reactions of the Krebs cycle and therefore play an essential role in intermediary metabolism and production of ATP. Thiamine deficiency is common in septic patients and is associated with an increased risk of death. For these reasons thiamine was added to the “metabolic resuscitation protocol”.
Several studies have administered vitamin C in doses exceeding 100g/day as adjuvant therapy in patients with cancer (excluding those with chronic renal failure) with no discernable side effects. [28-35] Vitamin C appears to be toxic to normal human cells (not cancer cells) at a concentration on greater than 25 mM.  A dose of 6g/day will achieve a steady state serum concentration of about 240uM [36-38] which is about 100 times less than the dose required to cause cellular toxicity. The package insert for vitamin C  lists no contraindications or adverse effects of the drug and states that as much as “6 grams has been administered without evidence of toxicity”. The package insert lists “acute Vitamin C deficiency” as the major indication for IV Vitamin C administration… it should noted noted that Vitamin C levels are undetectable or extremely low in critically ill patients. The only reported restriction to the use of high dose intravenous vitamin C is in patients with known glucose-6-phospahte deficiency (G6PD) in whom hemolysis has been reported, [40,41] and in patients with chronic renal failure who are at risk of hyper-oxalosis.
Patents with sepsis predictably have very low serum vitamin C levels, which can only be corrected with intravenous vitamin C in a dose of more than 3gm per day. [14,36,38] Based on published clinical data, vitamin C pharmacokinetic modeling as well as the package insert, we decided to administer 6 gm vitamin C per day divided in 4 equal doses as part of our “metabolic resuscitation protocol”. [11,14,15,36-39] This dosage is devoid of any reported complications or side effects. This dose of Vitamin C has proven anti-oxidant effects without any evidence of pro-oxidant activity. Hydrocortisone was dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine was included in the Vitamin C protocol at a dose of 200mg q 12 hourly.[27,43] This dosage strategy is listed below.
Vitamin C, Hydrocortisone and Thiamine dosing protocol
Vitamin C: Vitamin C is provided by the manufacturer as a 50 ml vial at a concentration of 500mg/ml. Three (3) ml of vitamin C is placed in a 50ml bag of Normal Saline (1500mg vitamin C in 50ml bag) which will then be infused over 1 hour. The dosing schedule is 1500mg every 6 hours for 4 days or until discharge from the ICU.
Once the vial is open, it is only stable for 6 hours. The resulting product is given 24 hours stability. When first ordered, 4 doses are made and then sent to the bed-side nurse. For the next day, the pharmacist will wait until 1 hour prior to the next dose to make the next batch. The acquisition cost of IV vitamin C as sold by Mylan Institutional LLC is $81 per vial. KRS Biotechnology (Boca Raton, FL) compounds a Vitamin C formulation (Tapioca) 500 mg/ml 50ml which has a 90 day shelf life from the time made and a 7 day shelf life after opening vial at a cost of $20 per vial.
Hydrocortisone: Patients are treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge. Optional dosing strategy: Hydrocortisone 50 mg bolus, followed by a 24-hour continuous infusion of 200 mg for 4 days.
Thiamine: Patients will receive intravenous thiamine 200mg q 12 hourly for 4 days or until ICU discharge. 
We did not invent vitamin C, hydrocortisone or thiamine. We hold no patents or intellectual property on these drugs nor the combination of drugs. The use of Vitamin C as part of our resuscitation protocol was built on the work of many investigators who preceded us, namely Dr. James Lind (1749) , Dr. Albert Szent-Gyorgyi (1928) , Dr. Fred Klenner (1949)  Professor Linus Pauling (1971-1986) [47-50], Dr. Arthur Kalokerinos (1960-1982) [51,52] Dr. Sebastian Padayatty (2004) , Dr John Wilson (2009-2013) [6,7] and Professor Alpha (Berry) Fowler [1,2,14], to name but a few. While we fortuitously come up with this combination of agents in an attempt to save the life of a patient, we do not claim “ownership” of this protocol. Furthermore, It is important to strongly emphasize the “metabolic resuscitation protocol” was not “sucked out of thin air” but rather is supported by a considerable body of basic- and clinical science. We believe that this exciting journey has just began and that there are still many questions to be answered.
Sepsis, Delirium and long-term Cognitive Dysfunction: Prevention Using Vitamin C??
Sepsis survivors are at an increased risk death, major adverse cardiovascular events, ischemic stroke, hemorrhagic stroke, myocardial infarction, recurrent sepsis and heart failure compared to population controls. [53,54] In addition, sepsis survivors incur long-term consequences, including developing new physical, psychiatric, and cognitive deficits. These deficits often limit their mobility and ability to perform day-to-day activities and impair quality of life.[54,55]
In addition to physical impairments, cognitive and neuropsychiatric complications are common following critical illness, particularly sepsis. The post sepsis-syndrome is similar in many respects to the post-traumatic stress disorder; patients suffer memory impairment, abnormalities of higher executive function, nightmares, anxiety disorders and depression. Semmler et al demonstrated that sepsis survivors showed cognitive deficits in verbal learning and memory and had a significant reduction of left hippocampal volume compared to healthy controls.
Delirium is very common in critically ill patients particularly those with sepsis. The risk of developing delirium is dependent on a complex interplay between predisposing and precipitating risk factors. Delirium is associated with negative outcomes including greater cognitive impairment after ICU discharge.[57,58] It is postulated that the neuro-psychiatric complications that occur in sepsis survivors may represent persistent neurological dysfunction initiated and or propagated by acute ICU delirium.
Vitamin C is concentrated almost 100-fold in neurons.[59-61] Vitamin C is an essential co-factor for the synthesis of dopamine, serotonin and norepinephrine. It is therefore not surprising that altered neuropsychiatric function has been reported in both the acute and chronic forms of scurvy.[62,63] Indeed, in the historical descriptions of scurvy, patients were described as having “gone insane”. Vitamin C levels are undetectable or very low in critically ill patients, particularly those with sepsis. Anecdotally, we have noted that none of our septic patients treated with our vitamin C protocol required treatment for delirium.
In an animal models, administration of ascorbic acid has been demonstrated to produce an antidepressant-like effect mediated by interaction with the monoaminergic and GABAa systems.[64,65] Gariballa evaluated the clinical significance of vitamin C deficiency among hospitalized acutely-ill older patients. In this study patients with vitamin C biochemical depletion had significantly increased symptoms of depression compared with those with higher concentrations at baseline and at 6 weeks. In a randomized controlled trial, Zhang et al demonstrated that 500 mg vitamin C PO BID improved the mood and decreased depression symptoms in a cohort of acutely hospitalized patients. In a randomized double-blind, placebo-controlled 14 day trial, Brody demonstrated that oral vitamin C resulted in a decrease in the Beck Depression scores with improved sexual intercourse frequency. A randomized, double-blind, placebo-controlled study in pediatric patients demonstrated that ascorbic acid was an effect adjunct to fluoxetine in the treatment of major depression.
We therefore propose/hypothesize that treatment with vitamin C during the acute phase of illness may limit the incidence and or severity/duration of delirium which may then limit or prevent the long-term neuro-psychiatric complications of sepsis. Furthermore, as treatment with the vitamin C cocktail reduces the duration of mechanical ventilation, duration of vasopressor support and duration of ICU stay we postulate that this intervention may promote early mobility and limit muscle loss thereby limiting critical illness myopathy (CIM) characteristic of critical illness and sepsis.
I will be posting my PowerPoint presentation on this topic as well as a Q/A post in response to all the questions received in a few days.
It should also be noted that “we” have received funding to do “large” RCT in the USA. Additional RCTs are being planned across the world.
- Fisher BJ, Seropian IM, Masanori Y et al. Ascorbic acid attenuates lipopolysaccharide-induced acute lung injury. Crit Care Med 2011; 39:1454-60.
- Fisher BJ, Kraskauskas D, Martin EJ et al. Attenuation of sepsis-induced organ injury in mice by vitamin C. JPEN 2014; 38:825-39.
- Han M, Pendem S, Teh SL et al. Ascorbate protects endothelial barrier function during septic insult: Role of protein phosphatase type 2A. Free Radic Biol Med 2010; 48:128.
- Kim SR. Ascorbic acid reduces HMGB1 secretion in lipopolysaccharide-activated RAW 264.7 cells and improves survival rate in septic mice by activation of Nrf2/HO-1 signals. Biochemical Pharmacology 2015; 95:279-89.
- Bornstein SR, Yoshida-Hiroi M, Sotiriou S et al. Impaired adrenal catecholamine system function in mice with deficiency of the ascorbic acid transporter (SVCT2). FASEB Journal 2003; 17:1928-30.
- Wilson JX. Mechanism of action of vitamin C in sepsis: ascorbate modulates redox signaling in endothelium. Biofactors 2009; 35:5-13.
- Wilson JX. Evaluation of vitamin C for adjuvant sepsis therapy. Antioxidants & Redox Signaling 2013; 19:2129-40.
- Marik PE. Critical illness related corticoseroid insufficiency. Chest 2009; 135:181-93.
- Minneci PC, Deans KJ, Eichacker PQ et al. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009; 15:308-18.
- Annane D, Bellisant E, Bollaert PE et al. Corticosteroids for treating sepsis (Review). Cochrane Database of Syst Rev 2015.
- Nathens AB, Neff MJ, Jurkovich GJ et al. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg 2002; 236:814-22.
- Tanaka H, Matsuda T, Miyagantani Y et al. Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective study. Arch Surg 2000; 135:326-31.
- Du WD, Yan ZR, Sun J et al. Therapeutic efficay of high-dose vitamin C on acute pancreatitis and its potential mechanisms. World J Gastroenterol 2017; 9:2565-69.
- Fowler AA, Syed AA, Knowlson S et al. Phase 1 safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med 2014; 12:32.
- Zabet MH, Mohammadi M, Ramezani M et al. Effect of high-dose ascorbic acid on vasopressor requirement in septic shock. J Res Pharm Pract 2016; 5:94-100.
- Okamoto K, Tanaka H, Makino Y et al. Restoration of the glucocorticoid receptor function by the phosphodiester compound of vitamins C and E, EPC-K1 (L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl hydrogen phosphate] potassium salt), via a redox-dependent mechanism. Biochem Pharmacol 1998; 56:79-86.
- Fujita I, Hirano J, Itoh N et al. Dexamethasone induces sodium-dependant vitamin C transporter in a mouse osteoblastic cell line MC3T3-E1. Br J Nutr 2001; 86:145-49.
- Azari O, Kheirandish R, Azizi S et al. Protective effects of hydrocortisone, Vitamin C and E alone or in combination against renal-ischemia-reperfusion injury rat. Iran J Pathol 2015; 10:272-80.
- Barabutis N, Khangoora V, Marik PE et al. Hydrocortisone and Ascorbic Acid synergistically protect against LPS-induced pulmonary endothelial barrier dysfunction. Chest 2017; In press.
- Marik PE, Khangoora V, Rivera R et al. Hydrocortisone, Vitamin C and Thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study. Chest 2017; ePub:http://dx.doi.org/10.1016/j.chest.2016.11.036.
- May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxidants & Redox Signaling 2013; 19:2068-83.
- Massey LK. Ascorbate increases human oxaluria and kidney stone risk. Journal of Nutrition 2005; 135:1673-77.
- Wandzilak TR. Effect of high dose vitamin C on urinary oxalate levels. Journal of Urology 1994; 151:834-37.
- Hoppe B, Beck BB, Milliner D. The primary hyperoxalurias. Kidney Int 2009; 75:1264-71.
- Sidhu H, Gupta R, Thind SK et al. Oxalate metabolism in thiamine-deficient rats. Ann Nutr Metab 1987; 31:354-61.
- Ortiz-Alvarado O, Muyaoka R, Kriedberg C et al. Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stone-forming patients. Urology 2011; 77:1054-58.
- Donnino MW, Andersen LW, Chase M et al. Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock: A pilot study. Crit Care Med 2016; 44:360-367.
- Ma Y, Chapman K, Levine M et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Science Translational Medicine 2014; 6:222ra18.
- Padayatty SJ, Rordan HH, Hewitt SM et al. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006; 174:937-42.
- Hoffer LJ, Robitaille L, Zakarian R et al. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PloS ONE 2015; 10:e0120228.
- Hoffer LJ, Levine M, Assouline S et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Annals of Oncology 2008; 19:1969-74.
- Stephenson CM, Levin RD, Spector T et al. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemotherapy & Pharmacology 2013; 72:139-46.
- Monti DA, Mitchell E, Bazzan AJ et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PloS ONE 2012; 7:e29794.
- Welsh JL, Wagner BA, van't Erve TJ et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 2013; 71:765-75.
- Ohno S, Ohno Y, Suzuki N et al. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Research 2009; 29:809-15.
- de Grooth HJ, Choo WP, Spoelstra-de Man AM et al. Pharmacokinetics of four high-dose regimens of intravenous Vitamin C in critically ill patients [Abstract]. Intensive Care Med 2016.
- Padayatty SJ, Sun H, Wang Y et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004; 140:533-37.
- Long CL, Maull KL, Krishman RS et al. Ascorbic acid dynamics in the seriously ill and injured. J Surg Res 2003; 109:144-48.
- Ascorbic Acid Injection. http://www.drugs.com/pro/ascorbic-acid-injection.html . 2015. The Torrance Company. 6-12-2016.
- Campbell GD, Steinberg MH, Bower JD. Ascorbic acid-induced hemolysis in G-6-PD deficiency [letter]. Ann Intern Med 1975; 82:810.
- Rees DC, Kelsey H, Richards JD. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 1993; 306:841-42.
- Marik PE, Pastores SM, Annane D et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36:1937-49.
- Flannery AH, Adkins DA, Cook AM. Unpeeling the evidence for the Banana Bag: Evidence-based recommendations for the management of alcohol-associated vitamin and electrolyte deficiencies in the ICU. Crit Care Med 2016; 44:1545-52.
- Stewart CP, Guthrie D. Lind's treatise on Scurvy. A bicentenary volume containing a reprint of the first editoion of A Treatise of the Scurvy by James Lind, MD, with additional notes. Edinburgh: Edinburg University Press; 1953.
- Szent-Gyorgyi A. Observations on the function of peroxidase systems and the chemistry of the adrenal cortex. Description of a new carbohydrate derivative. Biochemical Journal 1928; 22:1387.
- Klenner FR. The treatment of poliomyelitis and other virus diseases with vitamin C. South Med Surg 1949; 111:209-14.
- Pauling L. Vitamin C and common cold. JAMA 1971; 216:332.
- Pauling L. Are recommended daily allowances for vitamin C adequate? Proc Natl Acad Sci U S A 1974; 71:4442-46.
- Pauling L, Anderson R, Banic S et al. Workshop on vitamin C in immunology and cancer. International Journal for Vitamin & Nutrition Research – Supplement 1982; 23:209-19.
- Pauling L, Moertel C. A proposition: megadoses of vitamin C are valuable in the treatment of cancer. Nutr Rev 1986; 44:28-32.
- Kalokerinos A. Some aspects of aboriginal infant mortality. Med J Australia 1969; 1:185-87.
- Kalokerinos A, Dttman I, Dettman G. ASCORBATE- The Proof of the Pudding. A selection of case histories responding to ascorbate. Australasian Nurses J 1982;18-21.
- Ou SM, Chu H, Chao PW et al. Long-term mortality and major adverse cardiovascular events in sepsis survivors. A Nationwide population-based study. Am J Respir Crit Care Med 2016; 194:209-17.
- Winters BD, Eberlein M, Leung J et al. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 2010; 38:1276-83.
- Karlsson S, Ruokonen E, Varpula T et al. Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med 2009; 37:1268-74.
- Semmler A, Widmann CN, Okulla T et al. Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors. J Neurol Neurosurg Psy 2013; 84:62-69.
- Zaal IJ, Devlin JW, Peelen LM et al. A systematic review of risk factors for delirium in the ICU. Crit Care Med 2015; 43:40-47.
- Girard TD, Jackson JC, Pandharipande P et al. Delirium as a predictor of long-term cognitive impairement in survivors of critical illness. Crit Care Med 2010; 38:1513-20.
- Burzle M, Hediger MA. Functional and physiological role of vitamin C transporters. Curr Top Membr 2012; 70:357-75.
- Burzle M. The sodium-dependent ascorbic acid transporter family SLC23. Molecular Aspects of Medicine 2013; 34:436-54.
- Gess B. Ascorbic acid and sodium-dependent vitamin C transporters in the peripheral nervous system: from basic science to clinical trials. Antioxidants & Redox Signaling 2013; 19:2105-14.
- Stewart CP, Guthrie D. Lind's treatise on scurvy. A bicentenary volume containing a reprint of the first editoion of A Treatise of the Scurvy by James Lind, MD, with additionalnotes. Edinburgh: Edinburg University Press; 1953.
- Rajakumar K. Infantile Scurvy: A historical Perspective. Pediatrics 2001; 108:1-3.
- Binfare RW. Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2009; 33:530-540.
- Rosa PB. Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors. Pharmacological Reports 2016; 68:996-1001.
- Gariballa S. Poor vitamin C status is associated with increased depression symptoms following acute illness in older people. International Journal for Vitamin & Nutrition Research 2014; 84:12-17.
- Zhang M. Vitamin C provision improves mood in acutely hospitalized patients. Nutrition 2011; 27:530-533.
- Brody S. High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial. Biological Psychiatry 2002; 52:371-74.
- Amr M. Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. Nutrition Journal 2013; 12:31.